Summary of Study ST002555

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR001647. The data can be accessed directly via it's Project DOI: 10.21228/M8T413 This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST002555
Study TitleEthnicity-Specific Differences in Ovarian Cancer Metabolic Signatures
Study TypeCultured cells
Study SummaryOvarian cancer is a leading cause of cancer-related deaths among women worldwide. Cancer cell metabolism plays a critical role in tumor growth and progression, and metabolic alterations in cancer cells have been implicated in treatment resistance. In this study, we performed metabolomic analysis using ovarian cancer cells derived from patients in the United States and Korea. Our results reveal significant ethnic-specific differences in the metabolic signatures of ovarian cancer cells, with differential regulation of metabolites derived from glycolytic pathways, lipid metabolism, and microbiome modified metabolites. These findings have important therapeutic implications, as differences in ovarian cancer metabolism between ethnic groups may influence treatment response and resistance. Targeting the unique metabolic signatures of ovarian cancer cells based on ethnic specificity may improve the effectiveness of precision medicine approaches in the treatment of ovarian cancer. This study highlights the potential for personalized and targeted therapeutic options based on the tumor metabolome and ethnic background of the patient. Overall, our results suggest that investigating ethnic-specific differences in cancer metabolism is critical for developing effective and personalized cancer therapies. The identification of unique metabolic signatures in ovarian cancer cells based on ethnic specificity provides a promising avenue for improving treatment outcomes and advancing the field of precision medicine in ovarian cancer.
University of Oklahoma Health Sciences Center
DepartmentCell Biology
LaboratoryDanny N. Dhanasekaran
Last NameJayaraman
First NameMuralidharan
Address975 NE 10th street BRC1468 Oklahoma City OK 73104
Phone405-271-8001 x30492
Submit Date2023-03-03
Num Groups3
Total Subjects48
Num Females12
Study CommentsOvarian cancer cell lines
Analysis Type DetailLC-MS
Release Date2023-04-25
Release Version1
Muralidharan Jayaraman Muralidharan Jayaraman application/zip

Select appropriate tab below to view additional metadata details:

Sample Preparation:

Sampleprep ID:SP002662
Sampleprep Summary:Samples were prepared using the automated MicroLab STARĀ® system from Hamilton Company. Several recovery standards were added prior to the first step in the extraction process for QC purposes. In order to dissociate small molecules bound to or trapped in proteins, lysate was precipitated with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) followed by centrifugation. The resulting extract was divided into five fractions: two for analysis by two separate reverse phase (RP)/UPLC-MS/MS methods with positive ion mode electrospray ionization (ESI), one for analysis by RP/UPLC-MS/MS with negative ion mode ESI, one for analysis by HILIC/UPLC-MS/MS with negative ion mode ESI, and one sample was reserved for backup. Samples were placed briefly on a TurboVapĀ® (Zymark) to remove the organic solvent. The sample extracts were stored overnight under nitrogen before preparation for analysis.